Can a rheumatoid arthritis drug tame immunotherapy side effects?
NCT ID NCT04305145
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researchers will compare how many achieve symptom relief without needing long-term steroids after 7 weeks. The goal is to find a safer, more effective way to manage this common side effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab (a drug that blocks inflammation)
What this could lead to
If it works, this could offer a more effective, steroid-free way to manage severe colitis caused by immunotherapy, allowing patients to better tolerate cancer treatment.
What could go wrong
This is a small, early-phase trial with only 42 participants. Infliximab may not work better than steroids, and it carries risks like infection or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.